Loading stock data…
PSNL
$5.78+0.26 (+4.71%)
Market ClosedLast close May 1
Personalis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Personalis, Inc. in the Healthcare sector is trading at $5.78. The stock is currently 50% below its 52-week high of $11.50, remaining 22.9% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why PSNL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.78
Potential Upside
5%
Whystock Fair Value$6.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$660.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.96%
Volume
Today's trading volume
1.97M
Recent News
How The Personalis (PSNL) Story Is Shifting With Cautious Targets And Execution Risks
The analyst fair value estimate for Personalis has been nudged to US$11.29 from US$11.00, a small adjustment that still matters if you are tracking valuation closely. This shift aligns with recent, more cautious commentary that balances higher expected net losses and spending with an unchanged rating. Together, these factors signal a blend of potential and execution risk. As you read on, you will see how this updated price target fits into the broader narrative and what to watch to stay on...
Morgan Stanley Lowers Personalis (PSNL) Price Target to $10
Personalis, Inc. (NASDAQ:PSNL) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its price target from Morgan Stanley lowered from $11 to $10. The firm’s analyst maintained an Equal Weight rating on the stock after updating its estimates to reflect an […]
Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK)
Specializing in AI-driven autonomy for commercial and defense vehicles, Kodiak AI targets clients seeking advanced navigation solutions.
Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares
Navan delivers AI-powered travel and expense management solutions for enterprise clients in the business software sector.
Personalis, Inc. Q4 2025 Earnings Call Summary
Moby summary of Personalis, Inc.'s Q4 2025 earnings call